12:00 AM
Jul 23, 2012
 |  BC Week In Review  |  Company News  |  Deals

BioTime, Jade Therapeutics deal

BioTime granted Jade an exclusive sublicense to use HyStem hydrogels for facilitating time-release topical delivery of recombinant human growth hormone to treat...

Read the full 88 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >